|1.||Vaughan, Douglas E: 30 articles (01/2015 - 05/2002)|
|2.||Schmitt, Manfred: 29 articles (04/2014 - 01/2002)|
|3.||Lawrence, Daniel A: 24 articles (06/2014 - 01/2003)|
|4.||Brünner, Nils: 20 articles (07/2011 - 01/2002)|
|5.||Jankun, Jerzy: 19 articles (07/2015 - 01/2003)|
|6.||Sobel, Burton E: 19 articles (12/2013 - 08/2002)|
|7.||Declerck, Paul J: 18 articles (04/2015 - 07/2002)|
|8.||Carmeliet, Peter: 18 articles (07/2014 - 03/2002)|
|9.||Harbeck, Nadia: 18 articles (01/2014 - 01/2002)|
|10.||Schmitt, M: 18 articles (05/2013 - 01/2000)|
09/01/2015 - "Analyses of 4 phenotypes, defined by tumor size and PAI-1 status, revealed that patients bearing either pT1 tumors, irrespective of PAI-1 levels, or pT2,3 tumors with low PAI-1 levels, had similar disease-free interval probabilities and showed favorable outcome compared to those bearing pT2,3 tumors with high PAI-1 levels. "
10/01/2007 - "Intuitively, increased levels of PAI-1 should be beneficial in downregulating uPA activity, particularly in cancer. "
05/01/2002 - "At baseline, cancer patients had FVIIa, F1+2, TAT, and PAI-1 significantly greater than control subjects. "
02/15/1998 - "When only the immunoreactive scores that were classified as "high" (if the score was > or = 5 or > or = 1, for tumor epithelial and stromal cells, respectively) were considered, univariate analysis revealed that a "high" PAI-1 score for tumor epithelial cells and a "high" uPAR score for stromal cells both were significantly associated with poor disease free and overall survivals, particularly early period survival. "
07/01/1997 - "In cancer, increase of uPA, uPA-R, and/or PAI-1 is associated with tumor progression and with shortened disease-free and/or overall survival in patients afflicted with malignant solid tumors. "
03/11/2010 - "To mechanistically elucidate the role of PAI-1 in cardiac fibrosis, 12-week-old mice were chosen to study the biologic events leading to fibrosis. "
03/11/2010 - "The goal of this study was to determine the effect of a PAI-1 deficiency (PAI-1(-/-)) on the spontaneous development of cardiac fibrosis. "
02/01/2005 - "In this study, the effect of pharmacological PAI-1 inhibition in a mouse model of Ang II-induced vascular remodeling and cardiac fibrosis was examined. "
02/01/2005 - "Future studies are needed to determine whether the interactive effect of Ang II/salt and reduced PAI-1 activity on cardiac fibrosis is species-specific. "
10/01/2015 - "The activation of HIF-1α may promote fibrogenesis by an increase of PAI-1 expression and a subsequent elevation of extracellular matrix production in oral submucosa leading to fibrosis."
07/01/2014 - "The most interesting findings of our study, to our knowledge the largest series reporting PAI-1 levels during follow-up in septic patients, were that plasma PAI-1 levels during the first week were associated with inflammation, severity and mortality."
09/01/2012 - "The relation between PAI-1 and inflammation is of particular interest, but current knowledge regarding regulation of PAI-1 in adipose tissue is mainly based on animal studies or ex vivo experiments on human cultured adipocytes. "
03/01/2008 - "The results from that study also indicated that PAI-1 plays a critical role in both acute and chronic hepatic inflammation. "
01/01/2015 - "IMD-4690 is a newly synthesized inhibitor for PAI-1, whereas the effect on allergic airway inflammation and remodeling is still unclear. "
12/01/2014 - "However, PAI-1 KO mice fail to terminate inflammation, which may significantly contribute to the development of tympanosclerosis in PAI-1 KO mice. "
|4.||Weight Loss (Weight Reduction)
11/01/2004 - "In addition, weight loss by dietary restriction or comprehensive lifestyle modification is effective in lowering PAI-1 plasma levels. "
11/01/2001 - "This study aimed to assess PAI-1 expression in these two fat territories in obese and lean subjects and to determine if concomitant changes of plasma and adipose tissue PAI-1 values occur after weight reduction. "
08/01/2001 - "The aim of the present study is to evaluate the effect of weight loss and the influence of the PAI-1 promoter 4G/5G genotype on the fibrinolytic system and lipid parameters in obese children. "
04/01/1998 - "Study of correlations between anthropometric parameters and PAI-1 and evaluation of the changes induced by weight loss. "
11/01/2014 - "We examined the associations of fiber intake and its changes with PAI-1 before and during an intensive lifestyle intervention (ILI) for weight loss in 1,701 Look AHEAD (Action for Health in Diabetes) participants with dietary, fitness, and PAI-1 data at baseline and 1 year. "
01/01/1998 - "These results indicate that the G-->T mutation coding for factor XIIIVal34Leu is protective against myocardial infarction and suggest a mechanism whereby elevated levels of PAI-1 may contribute to vascular risk."
09/01/2012 - "In this study, we examined the relationship between PAI-1 4G/5G polymorphism and patency of the infarct-related artery after thrombolysis in patients with ST-elevation myocardial infarction (STEMI). "
07/23/2002 - "This study describes the age-dependent development of spontaneous coronary arterial thrombi that are associated with evidence of subendocardial myocardial infarction in mice transgenic for human PAI-1. "
08/01/2000 - "The present study evaluated the concentrations of PAI-1 and several fibrinolytic factors in the plasma and platelets of patients with CAD and the serial changes in patients with acute myocardial infarction (AMI). "
10/01/1998 - "In conclusion, in the present study neither homozygosity for the 4G allele of the PAI-1 4G/5G-polymorphism nor the FV:Q506 mutation led to an increased risk of myocardial infarction in young men."
|1.||Plasminogen Activators (Plasminogen Activator)
|4.||Tissue Plasminogen Activator (Alteplase)
|6.||Urokinase-Type Plasminogen Activator (Urokinase)
|7.||Messenger RNA (mRNA)
|8.||Fibrinogen (Factor I)
|9.||Plasminogen Activator Inhibitor 2
|10.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|3.||Angioplasty (Angioplasty, Transluminal)